Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Western Alliance Q3 2026 net income rises 6% year-over-year to $277.2 million

Western Alliance Q3 2026 net income rises 6% year-over-year to $277.2 million

BitgetBitget2026/10/19 20:29
  • Western Alliance’s third-quarter 2026 net income rose 6% year-over-year to $277.2 million.
  • Net revenue climbed 8% from the third quarter of 2025 to $1 billion.
  • Net loan charge-offs fell 17% from the second quarter of 2026 to $45.8 million.
  • Share repurchases totaled $92.1 million during the third quarter of 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Western Alliance Bancorporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-066286), on October 19, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"Demand destruction" and tug-of-war over Saudi attack risks, international oil prices fall more than 2%

Traders weighed the impact of Saudi attack risks and sharply reduced demand, causing oil prices to fall more than 2%.

智通财经•2026/10/26 06:41
"Demand destruction" and tug-of-war over Saudi attack risks, international oil prices fall more than 2%

JPMorgan maintains "Neutral" rating on Johnson & Johnson (JNJ.US): Strong data from two anti-cancer drugs, but valuation premium limits upside potential

Johnson & Johnson’s new prostate cancer drug and head and neck cancer drug Ervantumab both released positive data at ESMO. JPMorgan stated that the pipeline shows differentiated potential but valuations are relatively high, maintaining a Neutral rating.

智通财经•2026/10/26 06:37